Vaccine maker Moderna forecasts lower sales next year, shares tumble 17% to near four-year low
Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key products and predicted 2025 sales below its forecast for the current year, sending its shares closer to a four-year low. Shares of the vaccine maker tumbled 17.1% to $65.88 at midday. The company expects sales…